Evidence map›Paper›PMID 34213626›Full record

ReviewCurrent treatment options in oncology2021

Precision Therapy for Brain Tumors in Hereditary Syndromes.

Gerald C Wallace, Madeleine Tjoelker, Kaitlyn Bartley, John W Henson

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gerald C WallaceNeurology Residency Program, Medical College of Georgia, 1120 15th Street, Augusta, GA, 30912, USA.
Madeleine TjoelkerHereditary Cancer Clinic, Georgia Cancer Center, Medical College of Georgia, Augusta University, 1411 Laney Walker Blvd, Augusta, GA, 30912, USA.
Kaitlyn BartleyGeorgia Cancer Center, Medical College of Georgia, Augusta University, 1411 Laney Walker Blvd, Augusta, GA, 30912, USA.
John W HensonGeorgia Neurofibromatosis Clinic, Brain Tumor Program and Hereditary Cancer Clinic, Georgia Cancer Center, Medical College of Georgia, Augusta University, 1411 Laney Walker Blvd, Augusta, GA, 30912, USA. johenson@augusta.edu.
Augusta University · USCancer Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementNervous system tumors arising in the setting of monogenic, hereditary cancer predisposition syndromes are unique in that the initiating genetic event in tumor formation is known. This knowledge provides a powerful treatment approach if the alteration or pathway can be targeted with a therapeutic agent. A reasonable argument can be made for the use of targeted agents in these tumor patients, even though many of them have FDA approval only for other tumor types. It is our practice to use and employ targeted therapy when standard treatments have failed or represent an unattractive option. Over time, however, targeted therapies will likely become first-line options.

Indexed as

Molecular Targeted TherapyPrecision MedicineBiomarkers, TumorBrain NeoplasmsClinical Decision-MakingCombined Modality TherapyDisease ManagementDisease SusceptibilityGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansNeoplastic Syndromes, HereditarySignal TransductionTreatment OutcomeBiomarkers, TumorBrain tumorGeneticHereditaryPrecisionTargeted

Identifiers

PMID34213626
OpenAlexW3176444569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.